Genespire and SR-TIGET Show Durable Preclinical Efficacy ofLiver-Directed Gene Therapy for Methylmalonic Acidemia by Harry Fowler | Jul 8, 2026 | News
Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic by Harry Fowler | Sep 25, 2024 | News
Genespire Presents Positive Preclinical Proof of Concept Data at the ASGCT Annual Meeting by Harry Fowler | May 9, 2024 | News
Genespire appoints Jörn Aldag as Chairman of the Board of Directors by Harry Fowler | Jul 2, 2020 | News
